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868Bone Marrow or Peripheral BloodA 40-year-old otherwise healthy man was diagnosed with chronic myelogenous leukemia (CML) in the first
chronic phase 6 months ago after a routine annual examination. He took imatinib mesylate for 3 months
but experienced intolerable side effects that resolved with discontinuation of the drug. He is about to undergo
a myeloablative transplant from his HLA-matched brother.
Which stem cell source would you use?
 Bone marrow
 Peripheral blood
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In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge
and invited to use an online poll to recommend a course
of treatment. The reader recommendations for ther-
apy were:
 58% Bone marrow
 42% Peripheral blood
COMMENTARY
Among adults, peripheral blood grafts are the main
stem cell source for both related and unrelated donor
transplants. Some reports including randomized clini-
cal trials suggest transplantation of peripheral blood
progenitor cells (PBPC) fromanHLA-matched sibling
may offer advantages over the transplantation of bone
marrow (BM) in terms of leukemia-free (LFS) and
overall survival (OS) [1-3]. All of these reports docu-
mented faster rates of hematopoietic recovery after
transplantation of PBPC compared to BM. However,
chronic graft-versus-host disease (cGVHD) rates are
higher after transplantation of PBPC than after BM
[1,4,5]. In patients with chronicmyelogenous leukemia
(CML) in the first chronic phase the early LFS and OS
rates are similar after PBPC and BM transplants [1,2].
However, observational studies suggest when these
patients are followed for a longer period (.6 years),
the rates of treatment-related mortality (TRM), treat-
ment failure (inverse of LFS), and overall mortality are
higher after PBPC compared to BM transplants [5].
Shownbeloware6-yearLFSrates (61%versus. 41%)af-
ter BM and PBPC transplants, respectively, for patients/$36.00/0
6/j.bbmt.2008.05.015reported to theCenter for International Blood andMar-
row Transplant Research and the European Group for
Blood and Marrow Transplantation [5]. Patients in-
cluded in this report [5] were initially reported in 2000
[1] (early transplant outcomes,median follow-up1 year).
In a small study, granulocyte mobilized BMwas as-
sociated with hematopoietic recovery rates compara-
ble to PBPC grafts and lower rates of cGVHD but
without a survival advantage [6]. However, the optimal
dosing and scheduling of growth factor before harvest
and long-term outcome after transplantation of mobi-
lized BM has yet to be determined.
Otherwise healthy patients with CML in the first
chronic phase have relatively low TRM and relapse
rates after transplantation of BM, leaving little to
gain from faster recovery of hematopoiesis and higher
cGVHD with PBPC. Therefore, I would favor trans-
plantation of a BM graft for this patient.
Mary Eapen, MBBS
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